Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

Business Wire January 8, 2020

UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101

Business Wire December 19, 2019

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 6, 2019

UroGen to Present at November 2019 Investor Conferences

Business Wire November 18, 2019

UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

Business Wire November 12, 2019

UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

Business Wire November 11, 2019

UroGen To Present at October 2019 Investor Conference

Business Wire September 30, 2019

UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

Business Wire September 24, 2019

UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer

Business Wire September 24, 2019

UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

Business Wire September 10, 2019

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 6, 2019

UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

Business Wire August 9, 2019

UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019

Business Wire August 5, 2019

UroGen Pharma Joins Russell 3000® Index

Business Wire July 1, 2019

UroGen Pharma to Present at June 2019 Investor Conferences

Business Wire May 30, 2019

UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments

Business Wire May 9, 2019

UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

Business Wire May 5, 2019

UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

Business Wire May 2, 2019

UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

Business Wire April 23, 2019

UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer

Business Wire April 5, 2019